Request Demo

Last update 23 Jan 2025

Levothyroxine Sodium

Last update 23 Jan 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryLevothyroxine Sodium is a fascinating small molecule drug that acts as a synthetic version of the thyroid hormone and targets the thyroid hormone receptor as a thyroid hormone agonist. Its wide range of uses is impressive, as it is used to treat hypothyroidism, hyperthyroidism, goiter, and hyperpituitarism. Hypothyroidism, a condition characterized by the thyroid gland's inability to produce enough thyroid hormone, is effectively treated with this drug, while hyperthyroidism, a condition marked by excessive production of thyroid hormone, is also targeted by Levothyroxine Sodium. Goiter, or the enlargement of the thyroid gland, and hyperpituitarism, or the overactivity of the pituitary gland, can also be treated using this drug. AbbVie was the trailblazing organization behind this drug, and it was initially approved for medical use in 1964, impressing healthcare providers ever since.

Drug Type

Small molecule drug

Synonyms

LT4, Levothyroxine Sodium Hydrate, Sustained-release T4

+ [29]

Target

THR

Mechanism

THR agonists(Thyroid hormone receptor agonists)

Therapeutic Areas

NeoplasmsNervous System DiseasesCongenital Disorders+ [3]

Active Indication

Differentiated Thyroid Gland CarcinomaMyxedema comaHyperpituitarism+ [6]

Inactive Indication-

Originator Organization

AbbVie, Inc.

Active Organization

Azurity Pharmaceuticals, Inc.Xeris Biopharma Holdings, Inc.Shenzhen Zhonglian Guangzhen Pharmaceutical Group Co. Ltd.

+ [13]

Inactive Organization

BERLIN-CHEMIE AG

Genus Lifesciences, Inc.

Alvogen, Inc.

Drug Highest PhaseApproved

First Approval Date

JP (07 Aug 1964),

Hypothyroidism

RegulationOrphan Drug (US)

Structure/Sequence

Molecular FormulaC15H11I4NNaO4

InChIKeyBRLSOHUOWVCKNI-YDALLXLXSA-N

CAS Registry55-03-8

View All Structures (3)

277

Clinical Trials associated with Levothyroxine Sodium

NCT06647602

/ Not yet recruitingNot Applicable

Comparing Effects of Thyroid Hormone Medication Liothyronine and Levothyroxine in Treatment for Thyroid Cancer

This study will be a multicentre prospective cohort study on TH-substitution with liothyronine (L-T3) and levothyroxine (L-T4) in DTC patients after TH-withdrawal. The first cohort is patients treated in the University Medical Centre Groningen (UMCG) with L-T3 according to standard local protocol. The second cohort is patients treated in the Radboud University Medical Centre (Radboud UMC) with L-T4, also according to standard local protocol. We will compare effects of L-T3 or L-T4 on TSH, Thyroglobulin (Tg), quality of life (QoL), weight and cardiovascular parameters.

Start Date01 Feb 2025

Sponsor / Collaborator

University Medical Center Groningen

[+1]

ChiCTR2400095076

/ SuspendedNot ApplicableIIT

The role and mechanism of thyroid hormone in reducing bronchopulmonary dysplasia

Start Date01 Jan 2025

Sponsor / Collaborator-

NCT06731764

/ RecruitingPhase 2/3

Novel Approaches to the Treatment of Hypothyroidism

Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine.
There is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aimed at assessing levothyroxine/liothyronine combination therapy in patients living with hypothyroidism.
To address this knowledge gap we propose a randomized, three-arm, double-blind, controlled, escalating dose parallel pilot study whose results will lay the foundation of large multicenter trial(s) able to demonstrate the effectiveness (or lack thereof) of levothyroxine/liothyronine combination therapy.

Start Date10 Dec 2024

Sponsor / Collaborator

University of Connecticut Health Center

100 Clinical Results associated with Levothyroxine Sodium

100 Translational Medicine associated with Levothyroxine Sodium

100 Patents (Medical) associated with Levothyroxine Sodium

21,221

Literatures (Medical) associated with Levothyroxine Sodium

01 Jun 2025·Neural Regeneration Research

Dip2a regulates stress susceptibility in the basolateral amygdala

Article

Author: Chai, Weitai ; He, Xiaoxiao ; Zhu, Xiaojuan ; He, Zixuan ; Tian, Meng ; Li, Jing ; Yu, Huali

JOURNAL/nrgr/04.03/01300535-202506000-00025/figure1/v/2024-08-08T040853Z/r/image-tiff Dysregulation of neurotransmitter metabolism in the central nervous system contributes to mood disorders such as depression, anxiety, and post–traumatic stress disorder. Monoamines and amino acids are important types of neurotransmitters. Our previous results have shown that disco-interacting protein 2 homolog A (Dip2a) knockout mice exhibit brain development disorders and abnormal amino acid metabolism in serum. This suggests that DIP2A is involved in the metabolism of amino acid–associated neurotransmitters. Therefore, we performed targeted neurotransmitter metabolomics analysis and found that Dip2a deficiency caused abnormal metabolism of tryptophan and thyroxine in the basolateral amygdala and medial prefrontal cortex. In addition, acute restraint stress induced a decrease in 5-hydroxytryptamine in the basolateral amygdala. Additionally, Dip2a was abundantly expressed in excitatory neurons of the basolateral amygdala, and deletion of Dip2a in these neurons resulted in hopelessness-like behavior in the tail suspension test. Altogether, these findings demonstrate that DIP2A in the basolateral amygdala may be involved in the regulation of stress susceptibility. This provides critical evidence implicating a role of DIP2A in affective disorders.

15 Feb 2025·Biochemia Medica

Levothyroxine therapy reduces endocan and total cholesterol concentrations in patients with subclinical hypothyroidism

Article

Author: Jukić, Tomislav ; Bobetić-Vranić, Tanja ; Serdar Hiršl, Tihana ; Zec, Ivana ; Đurić, Koraljka ; Kraljević Šmalcelj, Marijana ; Somborac-Bačura, Anita ; Čeprnja, Marina

IntroductionSubclinical hypothyroidism (SCH) is an independent risk factor for cardiovascular diseases due to endothelial dysfunction and atherosclerosis development. The aim of this study was to determine whether the levothyroxine therapy could impact the concentrations of endothelial dysfunction blood markers, namely endothelin-1 (ET-1), asymmetric dimethylarginine (ADMA) and endocan, in patients with a mild form of SCH (thyroid-stimulating hormone (TSH) ≤ 10 mIU/L).Materials and methodsIn this case-control prospective study, SCH patients and healthy controls were recruited during their regular health examinations. Medical specialists prescribed levothyroxine to SCH patients if necessary. The endothelial dysfunction markers, as well as other biochemical markers, were measured in all subjects at baseline, and after 6 months of levothyroxine treatment following the euthyroidism.ResultsOur study showed higher ADMA (248.00 (168.78-540.20) vs. 166.30 (140.60-243.40) μg/L, P = 0.002), endocan (114.30 (63.45-194.65) vs. 67.26 (50.80-126.10) ng/L, P = 0.004), low-density lipoprotein cholesterol (LDL) (3.3 ± 0.6 vs. 3.7 ± 0.9 mmol/L, P = 0.043) and non-high-density lipoprotein cholesterol (non-HDL) (3.8 ± 0.7 vs. 4.2 ± 1.0 mmol/L, P = 0.020) concentrations in patients with a mild form of SCH in comparison with healthy subjects. In SCH patients, after 6 months of levothyroxine treatment following the euthyroidism, we observed a significant decrease in endocan (91.47 (61.88-200.03) vs. 97.90 (55.18-154.88) ng/L, P = 0.004), and total cholesterol concentrations (CHOL) (6.2 ± 1.0 vs. 5.8 ± 1.0 mmol/L, P = 0.039).ConclusionsA mild form of SCH is associated with higher concentrations of endocan, ADMA, LDL and non-HDL. The potential benefits of levothyroxine therapy were shown through the significant decrease of endocan and CHOL concentrations in SCH patients, thus contributing the atherosclerosis prevention.

01 Feb 2025·European Journal of Clinical Pharmacology

Pharmacotherapeutic actions related to drug interaction alerts – a questionnaire study among Swedish hospital interns and residents in family medicine

Article

Author: Svensson, Staffan A ; Wallerstedt, Susanna M ; Lönnbro, Johan ; Tukukino, Carina ; Parodi López, Naldy

AbstractPurposeTo explore how hospital interns and residents specialising in family medicine act on drug interaction alerts in a specific patient case, and on interaction alerts in general.MethodsA 4-page questionnaire, including a fictional patient case (73-year-old woman; 10 drugs in the medication list triggering 11 drug interaction alerts) and questions regarding the use of interaction alerts in general, was distributed to interns and residents during educational sessions (November‒December 2023). The respondents were instructed to consider what actions they would take “a normal day at work” due to the risk of interactions between the patients’ drugs. In the general questions, the respondents were asked how often they access the detailed interaction information (from 1 = never to 5 = always) provided by the knowledge resource, in relation to the alert classification (D = clinically significant, should be avoided; C = clinically significant, can be handled by, e.g., dose adjustment).ResultsThe questionnaire was completed by 55 interns and 69 residents (response rate: 98%). In the patient case, the respondents acted on a median of 4 (range: 0‒8) drugs, most often concerning repaglinide (in a D interaction alert with clopidogrel; 96% of the interns and 96% of the residents suggested action), and omeprazole (in three C interaction alerts with citalopram, clopidogrel, and levothyroxine, respectively; 71% and 83% suggested action). Among the respondents who answered the questions about how often (rated 4/5) they access more detailed information about interactions, 56 (59%) did so for D versus 29 (31%) for C alerts (P < 0.001).ConclusionPhysicians act on drug interaction alerts selectively, and the alert classifications seem to guide how they are used.

News (Medical) associated with Levothyroxine Sodium

10 Jan 2025

·xerispharma.com

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially 2024 financial results and 2025 outlook expected on March 6, 2025 CHICAGO--(BUSINESS WIRE)--Jan. 10, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announced 2024 total revenue guidance of $198 million to $202 million. The Company also anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, generating positive cash flow in the fourth quarter. “We achieved another record quarter of exceptional total revenue growth with revenues expected to be $60 million for the fourth quarter and $203 million for the full year representing growth of 35% and 24%, respectively. These impressive results are driven by accelerating demand for Recorlev and continued strong Gvoke demand,” said John Shannon, CEO of Xeris. “Our focus remains on continuing to drive exceptional product revenue growth and advancing our robust pipeline - namely our Phase 3 ready, XP-8121 program. With our commercial engine leading the way and our strong balance sheet, we are well positioned for a transformational 2025.” Other Fourth Quarter 2024 Updates Recorlev® achieved record number of new starts and referrals. Gvoke® ended the year with approximately 35% market share. Keveyis® maintained a similar number of patients on therapy as Q3 2024. Beta Bionics, Inc.: Xeris successfully formulated a unique XeriSol® formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter. Amgen: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect® formulation technology. The termination will not have a material impact on Xeris’ outlook. About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the financial outlook for 2024, including quarterly product revenue, projections regarding year-end 2024 cash estimates and total revenue, company performance in 2025, the potential for growth of revenue, the market, demand and therapeutic potential of its products and product candidates, the potential utility of its formulation platforms, the advancement of its pipeline (including XP-8121), the impact of the termination of the Amgen license agreement on our outlook, the timing of the release of our financial results and outlook, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators’ ability to protect its intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including those other risk factors identified in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Xeris' Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC), the contents of which are not incorporated by reference into, nor do they form part of, this communication. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.xerispharma.com, for a discussion of these and other risks and uncertainties. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20250110463157/en/ Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma Holdings, Inc.

License out/inFinancial StatementPhase 3

08 Jan 2025

·www.businesswire.com

Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression

SAN DIEGO--( BUSINESS WIRE )--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 clinical trial evaluating ABX-002, its highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment in adults with bipolar depression. The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipolar depression and will inform Autobahn’s further clinical development strategy. “Bipolar depression is one of the most prevalent and difficult-to-treat psychiatric conditions due to a host of burdensome symptoms,” said Roger McIntyre, MD, Professor of Psychiatry and Pharmacology at University of Toronto. “People living with bipolar disorder often experience prolonged periods of depression, many of whom are not adequately benefiting from, or have had difficulties tolerating, existing treatments. For decades, preclinical and clinical evidence has supported the effectiveness of thyroid hormone as an adjunctive treatment in adults living with bipolar depression, providing the basis for rigorously evaluating an optimized, brain-targeted, potent and selective TRβ agonist which could serve as a highly promising therapeutic option in the future.” The Phase 2 open-label trial will study ABX-002 as an adjunctive treatment in 30 adult patients with depressive episodes associated with bipolar I and bipolar II disorder and will utilize neuroimaging assessments and validated clinical scales to evaluate changes in metabolites associated with brain energy metabolism and improvements in depressive symptoms. The primary endpoints will be to assess the correlation of change from baseline of nucleoside triphosphate (NTP) and phosphocreatine (PCr) in the brain, as determined by phosphorus magnetic resonance spectroscopy imaging ( 31 P-MRS), with percent change in the Hamilton Depression Rating Scale-17 (HAMD-17) over six weeks of dosing, respectively. Key secondary and exploratory endpoints will evaluate changes from baseline in the HAMD-17, HAMD-29, as well as other neuroimaging assessments, including brain activity as measured by resting state functional magnetic resonance imaging (rs-fMRI). Autobahn anticipates reporting topline data from this study in the second half of 2025. “We are thrilled to initiate this Phase 2 trial of ABX-002, which we believe has the potential to reshape the treatment paradigm for bipolar depression, particularly as an adjunctive therapy for bipolar patients who do not experience adequate relief with their current antidepressant,” said Gudarz Davar, M.D., Executive Vice President, Head of Research and Development for Autobahn Therapeutics. “The clinical evidence generated to date for ABX-002 supports its promise as a centrally-active, differentiated thyromimetic, with a potentially favorable safety profile. This trial initiation expands our clinical depression program, and with our AMPLIFY trial in MDD also underway, sets up 2025 to be a transformational year with two Phase 2 trial readouts, bringing us markedly closer to our goal of addressing the unmet needs of patients living with depression worldwide.” ABX-002 is also being evaluated in the company’s ongoing AMPLIFY Phase 2 trial as an adjunctive treatment for patients with major depressive disorder (MDD), with topline data expected in the second half of 2025. About Autobahn Therapeutics Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com . About ABX-002 ABX-002 is an orally administered, potent and selective thyroid hormone beta receptor (TRβ) agonist designed to enhance the CNS benefits of thyroid hormone biology while also reducing the peripheral liabilities of synthetic thyroid hormone (e.g., triiodothyronine, T3), a treatment which has shown efficacy in numerous placebo-controlled human studies across MDD and bipolar disorder depression. Thyroid hormone agonism has demonstrated activity on cellular energy metabolism pathways, which play an important role on the regulation of brain bioenergetics and may be uniquely suited to address symptoms of atypical depression, a highly prevalent and underserved sub-population of MDD. In nonclinical and clinical studies, ABX-002 has demonstrated optimized PK properties, target engagement in brain regions associated with depression, and an attractive safety and tolerability profile.

Phase 2

23 Dec 2024

·endpts.com

Viatris' India-based manufacturing site blocked from shipping 11 generic drugs to US

Generic drug firm Viatris announced Monday that one of its India-based manufacturing facilities has been placed on import alert by the FDA following receipt of a warning letter for deficiencies cited from an inspection earlier this year. The company said 11 of its generic drugs will be barred from entering the US until the warning letter for the Indore, India-based site can be lifted. The company did not respond to a request for comment on which drugs have been halted entry to the US. However, due to drug shortages in the US, the FDA said four generic drugs made at the site are excluded from the import block, including levothyroxine sodium tablets, fingolimod capsules, atorvastatin tablets and metformin tablets. “Following the substance of FDA’s original inspection observations, we immediately implemented a comprehensive remediation plan at the site,” Viatris said in a statement on Monday. “The necessary corrective and preventive actions are well underway, including but not limited to related personnel actions. Additionally, we have engaged independent third-party subject matter experts to support the remediation plan.” The warning letter has yet to be released publicly. The company said the import alert does not affect its 2024 financial guidance, and it will incorporate potential future financial impact in its 2025 guidance early next year.

100 Deals associated with Levothyroxine Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D01010	Levothyroxine Sodium	H03AA01	DB00451

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Differentiated Thyroid Gland Carcinoma	US	Mylan Pharmaceuticals, Inc.	29 Apr 2022
Myxedema coma	US	Fresenius Kabi USA LLC	24 Jun 2011
Hyperpituitarism	US	King Pharmaceuticals Research & Development LLC	25 May 2001
Hyperthyroidism	CN	Shenzhen Zhonglian Guangzhen Pharmaceutical Group Co. Ltd.	01 Jan 2000
Thyroid Cancer	CN	Shenzhen Zhonglian Guangzhen Pharmaceutical Group Co. Ltd.	01 Jan 2000
Goiter	JP	ASKA Pharmaceutical Co., Ltd.	12 Feb 1998
Myxedema	JP	ASKA Pharmaceutical Co., Ltd.	12 Feb 1998
Congenital Hypothyroidism	JP	ASKA Pharmaceutical Co., Ltd.	07 Sep 1994
Hypothyroidism	JP	Takeda Pharmaceutical Co., Ltd.	07 Aug 1964

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypothyroidism	Discovery	US	Alvogen, Inc.	24 Oct 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04782856 (CTgov)	Phase 2	Hypothyroidism \| Goiter \| Thyroid Cancer	13	Placebo+Levothyroxine (Single Therapy)	ftuamuwmzo(kdtlgevuss) = bpawquulyu sydojdqbmr (tskqxbekjr, jnmkoyslsm - aqklvlvwjq) View more	-	14 Jun 2024
				Liothyronine+Levothyroxine (Combination Therapy)	ftuamuwmzo(kdtlgevuss) = jhvrsislvm sydojdqbmr (tskqxbekjr, lcxwukewnf - kohzrjebnu) View more
ENDO2024	Not Applicable	Congenital Hypothyroidism	105	levothyroxine (Transient CH)	mrcwaeqanl(bsgqbooxap) = wfqaenpnyo lnshoixajc (dapzflqpcw )	-	01 Jun 2024
				levothyroxine (Permanent CH)	mrcwaeqanl(bsgqbooxap) = ycpvzpbfjp lnshoixajc (dapzflqpcw )
ENDO2024	Not Applicable	-	-	Synthroid 150 mcg	qixftwopiw(dvzgiwyrng) = present zczggpqbwb (dtorrkodoq ) View more	-	01 Jun 2024
				IV Synthroid 500 mcg weekly infusions
ENDO2024	Not Applicable	Bipolar Disorder \| Thyrotoxicosis	-	Levothyroxine	ttrqnfjdpp(axcvwoiaop) = uumlzsobgm bcvszksuby (ornongvvnp )	-	01 Jun 2024
ENDO2024	Not Applicable	Hypothyroidism	45	LT4/LT3 combination therapy	ortcygcstf(fdccyhkfjn) = kleukfplja rkibqgilvq (diguwvxtpu ) View more	Positive	01 Jun 2024
				LT4 monotherapy	ortcygcstf(fdccyhkfjn) = htuqtqogre rkibqgilvq (diguwvxtpu ) View more
ENDO2024	Not Applicable	Hypothyroidism \| Rhabdomyolysis \| Nephrotic Syndrome	-	Levothyroxine	tdufzznkvx(anmnwvlqyu) = Rhabdomyolysis due to hypothyroidism, without an obvious precipitating factor, has been previously reported, but is very rare sfwnqrcgjs (lzkdzpynsy )	-	01 Jun 2024
				Liothyronine
ENDO2024	Not Applicable	Hypertriglyceridemia	-	Lovaza 2gm AM and 2gm PM	obyogydcjl(bqfuyaimot) = oqhkvgylee vvxbgwhbwn (affbmsrauk )	-	01 Jun 2024
				Synthroid 220 mcg IV daily	obyogydcjl(bqfuyaimot) = hzawkewicr vvxbgwhbwn (affbmsrauk )
NCT05823012 (Biospace) Manual	Phase 2	Hypothyroidism	46	XP-8121	(qvnqnwzgai) = oylfjtqjem dkwkjtaflg (swqbkrqnmf )	Positive	30 May 2024
DDW2024	Not Applicable	Nonalcoholic fatty liver	-	thyroid hormone (Control group (PBS))	nnfnmnanlp(ckyfnpiixf) = bhpqidsupq vipndzxkqb (egcgqwpihg ) View more	-	19 May 2024
				thyroid hormone (Treatment group (T3))	nnfnmnanlp(ckyfnpiixf) = goaqgcyqlc vipndzxkqb (egcgqwpihg ) View more
NCT04415658 (CTgov)	Phase 3	Heart Failure \| Brain Death	838	Thyroxine (Thyroxine)	qnckjzjudv(cjafpdbefz) = dwtmokajmu awrxtadtid (dzskclkgvh, wtlzktdist - fnqyfzxqag) View more	-	10 Jan 2024
				Saline (Saline Placebo)	qnckjzjudv(cjafpdbefz) = yuxwcgensq awrxtadtid (dzskclkgvh, rpffjzjahm - lytpzqfwxr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Levothyroxine Sodium

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation